Detection of ctDNA levels with the assay was correlated with detected changes in tumor burden in B-cell lymphoma patients treated with acalabrutinib.
A new study shows the MultiOmyx profile could improve disease assessment for both diseases using multiplex proteins.Read More
Ultra-sensitive detection of minimal residual disease now available to more people with blood cancers.Read More
Assay can aid physicians in better risk stratification and treatment of patients with diffuse large B-cell lymphoma.Read More
The test has been shown to offer sensitivity for the detection of residual cancer cells in marrow or blood.Read More